From NAT2 A803G samples however, frequency of 803AA was significantly higher among CML patients compared to the control, its presence being 55.5% and 29.0%, respectively (OR =0.044, 95% CI:0.020-0.095, p = 0. Here, NAT2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.